Journal
TRENDS IN MICROBIOLOGY
Volume 28, Issue 6, Pages 478-486Publisher
CELL PRESS
DOI: 10.1016/j.tim.2019.12.003
Keywords
-
Categories
Funding
- Catalyst Award from the Dr Ralph and Marian Falk Medical Research Trust
- Department of Defense (DoD)/Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-16-1-0691]
- Defense Threat Reduction Agency (DTRA) [HDTRA11810039]
- Stanford Advanced Residency Training at Stanford (ARTS) Fellowship Program
- U.S. Department of Defense (DOD) [HDTRA11810039] Funding Source: U.S. Department of Defense (DOD)
Ask authors/readers for more resources
There is an urgent need for prognostic assays to predict progression to severe dengue infection, which is a major global threat. While the majority of symptomatic dengue patients experience an acute febrile illness, 5-20% progress to severe infection associated with significant morbidity and mortality. Early monitoring and administration of supportive care reduce mortality and clinically usable biomarkers to predict severe dengue are needed. Here, we review recent discoveries of gene sets, anti-dengue antibody properties, and inflammatory markers with potential utility as predictors of disease progression. Upon larger scale validation and development of affordable sample-to-answer technologies, some of these biomarkers may be utilized to develop the first prognostic assay for improving patient care and allocating healthcare resources more effectively in dengue endemic countries.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available